Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
A Phase I/II Study of Nab-Paclitaxel and Carboplatin With Concurrent Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC)
Sponsor: National Cancer Institute (NCI)
Terminated
Ph I completed. Funding became unavailable causing Ph II to cease after two patients were enrolled.
Other terminated trials from National Cancer Institute (NCI)
A PHASE1/PHASE2 clinical study on Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 10 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .